When cartilage repair is the right choiceCartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.
When knee pain needs an orthopaedic assessmentMost knee pain settles with rest and physiotherapy; the threshold for orthopaedic assessment is persistent dysfunction despite weeks of conservative care, or acute structural changes—and assessment maps options rather than commits to surgery.Most knee pain settles with rest and physiotherapy; the threshold for orthopaedic assessment is persistent dysfunction despite weeks of conservative care, or acute structural changes—and assessment maps options rather than commits to surgery.
High tibial osteotomy as a first step in knee preservationHigh tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.High tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Medial knee pain that isn't a meniscus tearAround 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.Around 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.
Single-stage vs two-stage ACI for cartilage repairTraditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
The cost of leaving a knee cartilage defect untreatedKnee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.Knee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.
What ChondroFiller's CE approval means for UK patientsChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
How defect size and age decide OATS or OCADefect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.Defect size determines whether focal cartilage repair uses autograft (OATS, harvested from the patient's own knee) or donor allograft (OCA): below 2 cm², autograft is viable; above 4 cm², only allograft remains before arthroplasty.
Who qualifies for a ChondroFiller injectionChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
When cartilage repair makes sense before knee replacementTotal knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.Total knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.